CD8A and infection: Using this approach, we found that inhibition of LFA-1 during the entire anti-viral effector phase (until day 7 post-infection) impaired the magnitude of the CD8 TEFF response independently of the virulence of the LCMV strain used for challenge (ARM or CL13).